ImmunoACT
14 Oct 2023 2 mins Download PDF
Why in News?
- IIT Bombay-incubated Immunoadoptive Cell Therapy (ImmunoACT) has received Central Drugs Standard Control Organisation’s (CDSCO) marketing authorisation approval.
- ImmunoACT shall be the ‘first’ humanised CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product for relapsed/refractory B-cell lymphomas and leukaemia (blood cancer) in India.
- ImmunoACT uses NexCAR19, an indigenously developed CD19 targeted CAR-T cell therapy.
What is Immuno ACT?
The Immuno Act is legislation in the United States that provides liability protections for manufacturers of vaccines and other medical countermeasures during public health emergencies. Here are some key details about the Immuno Act:
So in summary, the Immuno Act provides legal immunity for vaccine makers to encourage development of medical countermeasures vital during public health emergencies like the COVID-19 pandemic. |
Related Article

Join Guru मार्गदर्शन ( Mentorship )
( First 5 Minutes Free )

Discuss Current Issues on Guru Forum
